| Mr Gary Keith Emerine, RPH | |
|
3925 Crosshaven Dr, Vestavia, AL 35243-5416 | |
| (205) 969-1260 | |
| (205) 969-2679 |
| Full Name | Mr Gary Keith Emerine |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 3925 Crosshaven Dr, Vestavia, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952619231 | NPI | - | NPPES |
| 183500000X | Other | AL | PHARMACIST TAXONOMY CODE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 9998 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Gary Keith Emerine, RPH 3925 Crosshaven Dr, Vestavia, AL 35243-5416 Ph: (205) 969-1260 | Mr Gary Keith Emerine, RPH 3925 Crosshaven Dr, Vestavia, AL 35243-5416 Ph: (205) 969-1260 |
News Archive
In keeping with China's often repressive policy towards news outlets and the dissemination of news and views that it doesn't want to be in the public domain, it is becoming apparent that Chinese social media WeChat and live-streaming app YY have long been editing what they display about the novel coronavirus illness.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.
A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
› Verified 4 days ago
Dr. Macie Lynn Sobers, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 737 Montgomery Hwy, Vestavia, AL 35216 Phone: 205-823-5442 Fax: 205-823-5853 | |
Mr. James Kevin Langston, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1745 Cedarwood Rd, Vestavia, AL 35216 Phone: 205-930-7004 Fax: 205-930-7410 | |
Dr. Kelley Crawford Brown, DOCTOR OF PHARMACY Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2004 Southwood Rd, Vestavia, AL 35216 Phone: 931-625-4568 | |
Tamara Renfrow, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4197 Crosshaven Dr, Vestavia, AL 35243 Phone: 205-967-4951 | |
Kelsey Knorr, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Vestavia Pkwy Ste 2300, Vestavia, AL 35216 Phone: 866-607-3561 | |
Ronda Lacey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4168 River View Cv, Vestavia, AL 35243 Phone: 205-305-2022 | |
Dr. Tyler Derrick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3201 Endeavor Ln, Vestavia, AL 35242 Phone: 205-421-2983 |